Pfenex Inc (PFNX) Short Interest Down 0.4% in February

Pfenex Inc (NYSEAMERICAN:PFNX) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 742,743 shares, a decline of 0.4% from the February 15th total of 746,051 shares. Approximately 2.4% of the company’s stock are short sold. Based on an average daily volume of 121,430 shares, the short-interest ratio is currently 6.1 days.

NYSEAMERICAN PFNX opened at $4.72 on Tuesday. Pfenex has a 12-month low of $3.13 and a 12-month high of $8.42.

Get Pfenex alerts:

Pfenex (NYSEAMERICAN:PFNX) last posted its earnings results on Monday, March 11th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.13.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in Pfenex in the fourth quarter valued at approximately $45,000. Rhumbline Advisers lifted its stake in Pfenex by 66.2% in the fourth quarter. Rhumbline Advisers now owns 33,921 shares of the biotechnology company’s stock valued at $108,000 after acquiring an additional 13,517 shares during the last quarter. Millennium Management LLC lifted its stake in Pfenex by 496.1% in the fourth quarter. Millennium Management LLC now owns 75,364 shares of the biotechnology company’s stock valued at $240,000 after acquiring an additional 62,722 shares during the last quarter. Falcon Point Capital LLC lifted its stake in Pfenex by 3.3% in the fourth quarter. Falcon Point Capital LLC now owns 80,205 shares of the biotechnology company’s stock valued at $256,000 after acquiring an additional 2,590 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Pfenex by 29.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 81,583 shares of the biotechnology company’s stock valued at $417,000 after acquiring an additional 18,750 shares during the last quarter.

PFNX has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Pfenex from a “buy” rating to a “hold” rating in a research report on Wednesday, November 14th. Wedbush reiterated an “outperform” rating on shares of Pfenex in a research note on Thursday, March 7th.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4214629/pfenex-inc-pfnx-short-interest-down-0-4-in-february.html.

About Pfenex

Pfenex Inc, a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study.

Read More: Channel Trading